91Ó°ÊÓ

A study reported by Griffin et al. compared the rate of pneumonia in \(1997-1999\) before pneumonia vaccine (PCV7) was introduced and in \(2007-2009\) after pneumonia vaccine was introduced. Read the excerpts from the abstract, and answer the question that follows it. (Source: Griffin et al., U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination, New England Journal of Medicine, vol. \(369: 155-163\), July 11,2013\()\) We estimated annual rates of hospitalization for pneumonia from any cause using the Nationwide Inpatient Sample database..... Average annual rates of pneumoniarelated hospitalizations from 1997 through 1999 (before the introduction of \(\mathrm{PCV} 7\) ) and from 2007 through 2009 (well after its introduction) were used to estimate annual declines in hospitalizations due to pneumonia. The annual rate of hospitalization for pneumonia among children younger than 2 years of age declined by 551\. 1 per 100,000 children \(\ldots\) which translates to 47,000 fewer hospitalizations annually than expected on the basis of the rates before PCV7 was introduced. Results for other age groups were similar. Does this show that pneumonia vaccine caused the decrease in pneumonia that occurred? Explain.

Step by step solution

01

Understanding the Provided Information

The first step is to comprehend the given data. From 1997-1999, before the introduction of the PCV7 vaccine, and from 2007-2009, after the PCV7 was introduced, average annual rates of pneumonia-related hospitalizations are compared. It is reported that hospitalization rates for pneumonia have declined annually, especially among children below 2 years of age.

02

Interpreting the Result

It is reported that the annual rate of hospitalization for pneumonia among children who are younger than 2 years has declined by 551.1 per 100,000 children. This is equivalent to 47,000 fewer hospitalizations annually than expected based on the rates before PCV7 was introduced. Similar results were apparent in other age groups. It's important to note that this is an observation after the introduction of the vaccine.

03

Establishing Cause and Effect

This is where the critical thinking comes in. While the data shows a decrease in hospitalization and the introduction of the PCV7 vaccine over a similar period, it cannot definitively establish that the vaccine is the cause of the decrease. Other factors may also have contributed to this decrease. Randomized controlled trials would be necessary to definitively state that the vaccine caused the decrease in hospitalization rates due to pneumonia.

Unlock Step-by-Step Solutions & Ace Your Exams!

• Full Textbook Solutions

  Get detailed explanations and key concepts

• Unlimited Al creation

  Al flashcards, explanations, exams and more...

• Ads-free access

  To over 500 millions flashcards

• Money-back guarantee

  We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91Ó°ÊÓ!

Key Concepts

These are the key concepts you need to understand to accurately answer the question.

Pneumococcal Vaccine

The pneumococcal vaccine, abbreviated as PCV7, plays a pivotal role in public health. It targets infections caused by the bacterium Streptococcus pneumoniae, which can lead to pneumonia, meningitis, and other serious illnesses. The introduction of PCV7 has significantly influenced healthcare practices, especially for young children who are more susceptible to these infections. This vaccine helps to develop immunity by introducing a small, harmless part of the bacteria to the body. As a result, the immune system learns to recognize and combat the actual bacteria should it invade. The effectiveness of such vaccines is measured through real-world studies, like the one conducted between 1997-2009, which compare health outcomes before and after the vaccine's introduction.

Public Health Impact

Public health impact refers to the broader effects of a healthcare intervention on a community or population at large. Introducing a vaccine like PCV7 can dramatically reduce the incidence of disease and consequently the rates of hospitalization. The decline in pneumonia-related hospitalizations indicates a positive public health impact. Besides reducing disease prevalence, vaccines also reduce healthcare costs, prevent complications, and improve quality of life. Evaluation of public health impact is crucial in determining the success of such interventions. Researchers observe trends over many years to distinguish between natural disease fluctuations and genuine improvements due to medical interventions.

Hospitalization Rates

Hospitalization rates for pneumonia provide a measurable outcome to assess the effect of public health interventions such as vaccination. A significant decline was noted in the annual rates of pneumonia-related hospitalizations for children under 2 years post-implementation of the PCV7 vaccine. Specifically, it contributed to 47,000 fewer hospitalizations annually, demonstrating a substantial decrease compared to pre-vaccination levels. These rates are used to gauge the vaccine's effectiveness in preventing severe manifestations of disease that require hospital care. By tracking such data, healthcare officials can make informed decisions on healthcare policies and resource allocation.

Cause and Effect Analysis

Cause and effect analysis helps in evaluating the relationship between an intervention and its outcomes. In the context of pneumococcal vaccination, while the reduction in pneumonia hospitalizations coincides with vaccine introduction, this alone does not confirm causation. Various external factors can influence outcomes, such as improvements in overall healthcare, public awareness, or even changes in diagnostic criteria. To conclusively establish that the vaccine is the cause of reduced hospitalization rates, randomized controlled trials (RCTs) are ideal as they eliminate external biasses and variables. RCTs allow researchers to attribute changes directly to the vaccine because they compare outcomes between a vaccinated group and a non-vaccinated group under controlled conditions.